Chlorotrianisene

Chlorotrianisene: Overview

Chlorotrianisene is a powerful synthetic, non-steroidal Hormone Modulator belonging to the stilbene derivative class. Historically, it was utilized in clinical medicine to supplement diminished estrogen levels, manage menopausal symptoms, and provide palliative treatment for specific hormone-dependent cancers.

What Is Chlorotrianisene & How Does It Work?

Chlorotrianisene functions as a potent Targeted Therapy agonist at estrogen receptors located throughout the body. At the cellular level, Chlorotrianisene is a highly lipophilic prodrug that is stored in adipose (fat) tissue and slowly released into the bloodstream, where it is converted by the liver into active estrogenic metabolites. These active compounds bind to estrogen receptors on target cells within the female reproductive tract, mammary glands, hypothalamus, and pituitary gland. This binding mimics the biological effects of naturally occurring estrogen, helping to relieve menopausal vasomotor symptoms, stimulate the development of female sexual characteristics, and suppress follicle-stimulating hormone (FSH) secretion from the anterior pituitary. In oncology, its estrogenic activity provides palliative suppression of androgen production in advanced prostate cancer.

Is Chlorotrianisene FDA Approved?

Chlorotrianisene received initial prescription approval from the United States Food and Drug Administration in 1952 under the brand name Tace. The medication was subsequently discontinued and voluntarily withdrawn from the US market as modern, safer steroidal estrogens and targeted hormone therapies became available. In historical Gynecology and oncology practice, physicians prescribed Chlorotrianisene for long-acting estrogen replacement and palliative cancer care.

What Is Chlorotrianisene Used For?

• Historical treatment of moderate to severe vasomotor symptoms of menopause (hot flashes, night sweats).
• Treatment of female hypogonadism, deficiencies in ovary function, and underdevelopment of female sexual characteristics.
• Historical palliative treatment of advanced, inoperable prostate cancer and prevention of postpartum breast engorgement.

Before Taking Chlorotrianisene: Contraindications & Precautions

Because Chlorotrianisene is a potent, long-acting synthetic estrogen, thorough clinical screening was mandatory to prevent severe cardiovascular and oncological complications.

Who Should Not Take Chlorotrianisene?

Chlorotrianisene is strictly contraindicated in patients with a known, suspected, or past history of breast cancer (except in specific palliative oncological protocols). It must never be administered to individuals with known or suspected estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, or a history of deep vein thrombosis (DVT) or pulmonary embolism. Patients with active liver disease, severe hepatic dysfunction, or a history of stroke or myocardial infarction must strictly avoid Chlorotrianisene.

Chlorotrianisene: Pregnancy & Fertility

Chlorotrianisene is strictly contraindicated during pregnancy, as synthetic estrogens can cause severe fetal harm, congenital malformations, and increased risks of clear cell vaginal carcinoma in female offspring (similar to diethylstilbestrol). It should not be used by nursing mothers, as estrogens reduce breast milk production and excrete into human milk. While historically used to treat certain types of infertility caused by estrogen deficiency, its long-acting nature made precise fertility cycle control difficult compared to modern treatments.

Tell Your Doctor Before Taking Chlorotrianisene

Inform your physician if you have a personal or family history of breast cancer, uterine cancer, or blood clotting disorders. Disclose any existing cardiovascular conditions, high blood pressure, diabetes, or gallbladder disease. Provide a complete list of all prescription medications, thyroid supplements, and over-the-counter drugs prior to initiating any hormone therapy.

Chlorotrianisene: Dosage & Administration

Chlorotrianisene was formulated as an oral capsule that provided prolonged, sustained estrogenic effects due to its storage in body fat.

• Oral Capsules: Administered by mouth, typically with food or milk to minimize gastrointestinal upset.
• Dosing Frequency: Administered in short cyclical courses or daily, depending on the specific medical indication.
• Drug Storage: Accumulated in adipose tissue, resulting in a delayed onset of action and prolonged effects after discontinuation.

Standard Chlorotrianisene Dosing

In historical clinical practice, the oral dosage of Chlorotrianisene for menopausal symptoms was 12 mg to 25 mg daily on a cyclical basis (e.g., 3 weeks on, 1 week off). For female hypogonadism, doses ranged from 12 mg to 25 mg daily for 21 days, followed by a progestin to induce withdrawal bleeding. For the palliative treatment of advanced prostate cancer, higher doses of 12 mg to 25 mg daily were administered continuously under strict oncological supervision. To prevent postpartum breast engorgement, 72 mg was given twice daily for two days.

How Chlorotrianisene Is Administered

Take Chlorotrianisene capsules by mouth with a full glass of water. Consuming the medication with food or immediately after a meal helps reduce the incidence of estrogen-induced nausea and gastric discomfort.

Chlorotrianisene: Clinical Efficacy & Research

Established clinical consensus confirmed that Chlorotrianisene was highly effective in suppressing severe menopausal vasomotor symptoms and providing long-acting estrogen replacement. Clinical trials demonstrated its unique pharmacokinetic profile, where storage in adipose tissue provided a smooth, sustained release of active estrogens, avoiding the rapid fluctuations seen with other oral preparations. However, long-term research revealed significant safety concerns associated with unopposed synthetic estrogens, including increased risks of endometrial cancer, thromboembolic events, and cardiovascular disease, which led to its clinical replacement by modern, safer bioidentical hormone replacement therapies.

Chlorotrianisene: Side Effects & Safety Profile

Chlorotrianisene exhibits a side effect profile typical of potent systemic estrogens, requiring vigilant monitoring for cardiovascular and gynecological risks.

Common Chlorotrianisene Side Effects

• Nausea, vomiting, and abdominal bloating
• Breast tenderness, enlargement, or nipple discharge
• Breakthrough vaginal bleeding or spotting
• Mild headache, fluid retention, and localized edema

Serious Chlorotrianisene Adverse Events

• Severe thromboembolic events, including deep vein thrombosis and pulmonary embolism
• Increased risk of myocardial infarction (heart attack) and ischemic stroke
• Increased risk of endometrial hyperplasia and endometrial cancer (if used without a progestin)
• Severe hepatic adenomas, jaundice, or gallbladder disease

Managing Chlorotrianisene Side Effects

If mild nausea occurs, ensure the medication is taken alongside a heavy meal. Discontinue Chlorotrianisene immediately and seek emergency medical evaluation if you experience sudden chest pain, severe shortness of breath, sudden severe headache, or swelling and pain in the lower legs.

Chlorotrianisene: Interactions & What to Avoid

Combining Chlorotrianisene with drugs that alter liver enzyme activity can significantly impact its conversion into active estrogenic metabolites.

Chlorotrianisene: Interactions

• Hepatic enzyme inducers (phenytoin, carbamazepine, rifampin): Accelerate the breakdown of estrogenic metabolites, potentially reducing the clinical efficacy of Chlorotrianisene.
• Thyroid hormone replacement therapy: Estrogens increase thyroid-binding globulin (TBG), requiring an increased dosage of levothyroxine in hypothyroid patients.
• Oral anticoagulants (warfarin): Estrogens alter the synthesis of blood clotting factors, potentially decreasing the effectiveness of blood thinners and requiring dose adjustments.

Chlorotrianisene: Food & Alcohol

Dietary intake does not significantly impair the absorption of Chlorotrianisene, and food helps reduce nausea. Excessive alcohol consumption should be avoided, as it can increase circulating estrogen levels and place additional metabolic stress on the liver.

Chlorotrianisene: Missed Dose, Overdose & Storage

Proper dosing adherence and safe storage practices are essential for medications with long-acting tissue accumulation.

Missed Dose of Chlorotrianisene

If an oral dose of Chlorotrianisene is missed, take it as soon as remembered unless it is almost time for the next scheduled dose. Skip the missed dose and resume your regular daily schedule. Do not take a double dose, as this increases the risk of severe nausea and fluid retention.

Chlorotrianisene: Overdose & Emergency

Overdosage of Chlorotrianisene produces severe nausea, vomiting, abdominal cramping, and withdrawal vaginal bleeding in females. Due to its storage in body fat, overdose effects may be prolonged. Emergency management involves immediate gastric decontamination, supportive intravenous hydration, and clinical observation.

How To Store Chlorotrianisene

Store Chlorotrianisene capsules at controlled room temperature between 15°C and 30°C (59°F and 86°F). Keep the medication container tightly closed, protected from light and moisture, and stored securely out of reach of children.

Chlorotrianisene: Patient Management & Monitoring

Systematic clinical and gynecological monitoring is mandatory during any systemic estrogen therapy to prevent severe long-term complications.

Tests Before Starting Chlorotrianisene

• Comprehensive physical examination, including blood pressure measurement, clinical breast examination, and pelvic examination.
• Baseline complete blood count, lipid profile, and liver function testing.

Monitoring During Chlorotrianisene Treatment

• Annual mammography and regular clinical breast examinations to screen for malignant breast changes.
• Regular monitoring of blood pressure, body weight, and clinical evaluation for signs of deep vein thrombosis.

Chlorotrianisene: Do’s and Don’ts

• Do perform regular breast self-examinations and report any unusual lumps or changes to your doctor.
• Do report any unexpected or heavy vaginal bleeding immediately.
• Don’t smoke cigarettes while taking systemic estrogens, as this drastically increases the risk of blood clots and stroke.
• Don’t ignore severe leg pain or sudden chest pressure during treatment.

Frequently Asked Questions

References

• United States Food and Drug Administration. Tace (Chlorotrianisene Capsules) Historical Approval and Discontinuation Documentation.
• DrugBank Online Database. Chlorotrianisene Compound Summary (Accession Number DB00269).
• National Center for Biotechnology Information. PubChem Compound Summary for Chlorotrianisene.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.